• Study of Enpatoran in Adults with Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE)

    Not recruiting

    2 1
    Investigated diseases:
    Bulgaria Greece Poland Romania Spain

  • Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

    Not recruiting

    3 1 1
    Investigated diseases:
    Bulgaria Czechia France Germany Italy Spain

  • Study of PRS-344/S095012 and obinutuzumab combination for patients with solid tumors – First human trial to evaluate safety and effectiveness

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Belgium France Spain

  • Study on the Effectiveness of Retifanlimab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Bulgaria Czechia

  • Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1 1
    Investigated diseases:
    Austria Belgium Czechia France Germany Hungary +5

  • Study on the Effectiveness and Safety of Alectinib, Entrectinib, and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Belgium France Germany Italy Poland Spain

  • Study on Atezolizumab with Radiotherapy for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Spain

  • Long-Term Study of Ritlecitinib Tosilate for Adults and Adolescents with Alopecia Areata

    Not recruiting

    3 1 1
    Investigated diseases:
    Czechia Germany Poland Spain

  • Study of Pembrolizumab, Epacadostat, and Drug Combination for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Portugal Spain

  • Study on Lorlatinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer After First-line Treatment Failure

    Not recruiting

    2 1 1 1
    Investigated diseases:
    France

powered by